Abatacept for the prevention of graft versus host disease in pediatric patients receiving 7/8 HLA-mismatched unrelated transplant for hematologic malignancies: a real-world analysis
Bone Marrow Transplantation, Published online: 14 August 2023; doi:10.1038/s41409-023-02034-zAbatacept for the prevention of graft versus host disease in pediatric patients receiving 7/8 HLA-mismatched unrelated transplant for hematologic malignancies: a real-world analysis (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - August 14, 2023 Category: Hematology Authors: Sharmila Raghunandan Lev Gorfinkel Brandi Bratrude Yvonne Suessmuth Kyle Hebert Donna Neuberg Kirsten M. Williams Michelle L. Schoettler Amelia A. Langston Leslie S. Kean Muna Qayed John Horan Benjamin K. Watkins Source Type: research
Real-World Data of Adherence and Drug Survival of Biologics in Treatment-Na ïve and Treatment-experienced Adult Patients with Rheumatoid Arthritis
CONCLUSION: Treatment choice primarily depends on disease activity and prognosis. Real-world data, showing differences in drug survival of bDMARDs and tsDMARD, can also be used in the variety of considerations when choosing treatment. Future studies could separate patients with RA into subgroups, which would also account for potential drug survival differences and enable personalized therapy.PMID:37566157 | DOI:10.1007/s12325-023-02607-w (Source: Adv Data)
Source: Adv Data - August 11, 2023 Category: Epidemiology Authors: Vered Rosenberg Gabriel Chodick Zhenyi Xue Freddy Faccin Howard Amital Source Type: research
Real-World Data of Adherence and Drug Survival of Biologics in Treatment-Na ïve and Treatment-experienced Adult Patients with Rheumatoid Arthritis
CONCLUSION: Treatment choice primarily depends on disease activity and prognosis. Real-world data, showing differences in drug survival of bDMARDs and tsDMARD, can also be used in the variety of considerations when choosing treatment. Future studies could separate patients with RA into subgroups, which would also account for potential drug survival differences and enable personalized therapy.PMID:37566157 | DOI:10.1007/s12325-023-02607-w (Source: Adv Data)
Source: Adv Data - August 11, 2023 Category: Epidemiology Authors: Vered Rosenberg Gabriel Chodick Zhenyi Xue Freddy Faccin Howard Amital Source Type: research
Real-World Data of Adherence and Drug Survival of Biologics in Treatment-Na ïve and Treatment-experienced Adult Patients with Rheumatoid Arthritis
ConclusionTreatment choice primarily depends on disease activity and prognosis. Real-world data, showing differences in drug survival of bDMARDs and tsDMARD, can also be used in the variety of considerations when choosing treatment. Future studies could separate patients with RA into subgroups, which would also account for potential drug survival differences and enable personalized therapy. (Source: Advances in Therapy)
Source: Advances in Therapy - August 11, 2023 Category: Drugs & Pharmacology Source Type: research
Non ‐Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN‐101)
ConclusionBoth CD28 and ICOS signaling play critical roles in inflammatory arthritis. Therapeutic agents such as acazicolcept that coinhibit both ICOS and CD28 signaling may mitigate inflammation and/or disease progression in RA and PsA more effectively than inhibitors of either pathway alone. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - July 28, 2023 Category: Rheumatology Authors: Stacey R. Dillon,
Lawrence S. Evans,
Katherine E. Lewis,
Susan Debrot,
Tiffany C. Blair,
Sherri Mudri,
Kayla Kleist,
Steven D. Levin,
Janhavi G. Bhandari,
Logan Garrett,
Martin F. Wolfson,
Pamela M. Holland,
Mark W. Rixon,
Stanford L. Peng Tags: Full Length Source Type: research
The podocyte: glomerular sentinel at the crossroads of innate and adaptive immunity
This report highlights recent progress in the field and emphasizes the importance of kidney transplantation and recurrent FSGS (rFSGS) as a platform for the study of primary FSGS. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - July 26, 2023 Category: Allergy & Immunology Source Type: research
Efficacy and safety of novel biologics in the treatment of lupus nephritis based on registered clinical trials: a systematic review and network meta-analysis
This study protocol has been registered with PROSPERO, with a registration number of CRD42021262498. (Source: Clinical and Experimental Medicine)
Source: Clinical and Experimental Medicine - July 18, 2023 Category: Research Source Type: research
Incident psoriasis under treatment with tumor necrosis factor- α inhibitors in juvenile idiopathic arthritis patients—analysis of the BiKeR registry
AbstractThe efficacy of tumor necrosis factor inhibitors (TNFi) for the treatment of psoriasis is well established, but patients may develop psoriasis for the first time while on TNFi as a paradoxical effect. Limited data on this association in patients with juvenile idiopathic arthritis (JIA) are available. Safety data from patients registered to the German Biologics registry (BiKeR) were analyzed. Patients were grouped by treatment regime: single TNFi, multiple TNFi, non-TNFi biologics or bDMARD-na ïve control group receiving methotrexate. TNFi-associated psoriasis was defined as incident diagnosis of psoriasis after st...
Source: Rheumatology International - July 16, 2023 Category: Rheumatology Source Type: research
Pharmacologic Treatment Strategies in Psoriatic Arthritis
Clin Ther. 2023 Jul 14:S0149-2918(23)00198-4. doi: 10.1016/j.clinthera.2023.05.010. Online ahead of print.ABSTRACTPURPOSE: The goal of this narrative review was to provide current data on psoriatic arthritis (PsA) therapeutic strategies, supporting treatment decisions with a domain-based approach.METHODS: This narrative review of treatment strategies for PsA focused on several disease domains (ie, peripheral arthritis, enthesitis, axial disease, dactylitis, skin and nail disease), as well as the so-called "related conditions" of uveitis, Crohn's disease, and ulcerative colitis. We searched PubMed, EMBASE, international gui...
Source: Clinical Therapeutics - July 16, 2023 Category: Drugs & Pharmacology Authors: G Ayan A Ribeiro Betul Macit Fabian Proft Source Type: research
Pharmacologic Treatment Strategies in Psoriatic Arthritis
Clin Ther. 2023 Jul 14:S0149-2918(23)00198-4. doi: 10.1016/j.clinthera.2023.05.010. Online ahead of print.ABSTRACTPURPOSE: The goal of this narrative review was to provide current data on psoriatic arthritis (PsA) therapeutic strategies, supporting treatment decisions with a domain-based approach.METHODS: This narrative review of treatment strategies for PsA focused on several disease domains (ie, peripheral arthritis, enthesitis, axial disease, dactylitis, skin and nail disease), as well as the so-called "related conditions" of uveitis, Crohn's disease, and ulcerative colitis. We searched PubMed, EMBASE, international gui...
Source: Clinical Therapeutics - July 16, 2023 Category: Drugs & Pharmacology Authors: G Ayan A Ribeiro Betul Macit Fabian Proft Source Type: research
Pharmacologic Treatment Strategies in Psoriatic Arthritis
Clin Ther. 2023 Jul 14:S0149-2918(23)00198-4. doi: 10.1016/j.clinthera.2023.05.010. Online ahead of print.ABSTRACTPURPOSE: The goal of this narrative review was to provide current data on psoriatic arthritis (PsA) therapeutic strategies, supporting treatment decisions with a domain-based approach.METHODS: This narrative review of treatment strategies for PsA focused on several disease domains (ie, peripheral arthritis, enthesitis, axial disease, dactylitis, skin and nail disease), as well as the so-called "related conditions" of uveitis, Crohn's disease, and ulcerative colitis. We searched PubMed, EMBASE, international gui...
Source: Clinical Therapeutics - July 16, 2023 Category: Drugs & Pharmacology Authors: G Ayan A Ribeiro Betul Macit Fabian Proft Source Type: research
Pharmacologic Treatment Strategies in Psoriatic Arthritis
Clin Ther. 2023 Jul 14:S0149-2918(23)00198-4. doi: 10.1016/j.clinthera.2023.05.010. Online ahead of print.ABSTRACTPURPOSE: The goal of this narrative review was to provide current data on psoriatic arthritis (PsA) therapeutic strategies, supporting treatment decisions with a domain-based approach.METHODS: This narrative review of treatment strategies for PsA focused on several disease domains (ie, peripheral arthritis, enthesitis, axial disease, dactylitis, skin and nail disease), as well as the so-called "related conditions" of uveitis, Crohn's disease, and ulcerative colitis. We searched PubMed, EMBASE, international gui...
Source: Clinical Therapeutics - July 16, 2023 Category: Drugs & Pharmacology Authors: G Ayan A Ribeiro Betul Macit Fabian Proft Source Type: research
Incident psoriasis under treatment with tumor necrosis factor- α inhibitors in juvenile idiopathic arthritis patients—analysis of the BiKeR registry
AbstractThe efficacy of tumor necrosis factor inhibitors (TNFi) for the treatment of psoriasis is well established, but patients may develop psoriasis for the first time while on TNFi as a paradoxical effect. Limited data on this association in patients with juvenile idiopathic arthritis (JIA) are available. Safety data from patients registered to the German Biologics registry (BiKeR) were analyzed. Patients were grouped by treatment regime: single TNFi, multiple TNFi, non-TNFi biologics or bDMARD-na ïve control group receiving methotrexate. TNFi-associated psoriasis was defined as incident diagnosis of psoriasis after st...
Source: Rheumatology International - July 15, 2023 Category: Rheumatology Source Type: research
Abatacept as Monotherapy and in Combination with Methotrexate in Patients with Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials
CONCLUSION: Abatacept monotherapy (SC and IV) was effective and well tolerated in children with pcJIA when prior MTX use was ineffective or not tolerated. Treatment effects of abatacept appear to be independent of MTX co-administration. Consequently, abatacept monotherapy can be considered for those with prior biologic therapy if MTX use is inappropriate.PMID:37453737 | DOI:10.3899/jrheum.2022-1320 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - July 15, 2023 Category: Rheumatology Authors: Nicolino Ruperto Daniel J Lovell Alberto Berman Jordi Anton Diego Oscar Viola Bernard Lauwerys Maria Elena Rama John Bohnsack Johannes Breedt Michel Fischbach Thomas Lutz Kirsten Minden Mahmood Ally Nadina Rubio-P érez Elisabeth Gervais Riana Van Zyl Rob Source Type: research
Abatacept as Monotherapy and in Combination with Methotrexate in Patients with Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials
CONCLUSION: Abatacept monotherapy (SC and IV) was effective and well tolerated in children with pcJIA when prior MTX use was ineffective or not tolerated. Treatment effects of abatacept appear to be independent of MTX co-administration. Consequently, abatacept monotherapy can be considered for those with prior biologic therapy if MTX use is inappropriate.PMID:37453737 | DOI:10.3899/jrheum.2022-1320 (Source: J Rheumatol)
Source: J Rheumatol - July 15, 2023 Category: Rheumatology Authors: Nicolino Ruperto Daniel J Lovell Alberto Berman Jordi Anton Diego Oscar Viola Bernard Lauwerys Maria Elena Rama John Bohnsack Johannes Breedt Michel Fischbach Thomas Lutz Kirsten Minden Mahmood Ally Nadina Rubio-P érez Elisabeth Gervais Riana Van Zyl Rob Source Type: research
